Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Seminars in Oncology
|
October 1, 1996
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)
W P McGuire, W J Hoskins, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study
W P McGuire, W J Hoskins, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study
F M Muggia, P S Braly, M F Brady, et al.
Gynecologic Oncology
|
August 15, 2019
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218
K N Slaughter Wade, M F Brady, T Thai, et al.
Current Oncology (Toronto, Ont.)
|
October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
A M Oza, V Castonguay, D Tsoref, et al.
The Journal of Urology
|
January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area
M S Soloway, S Beckley, M F Brady, et al.
The Journal of Urology
|
May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer
S A Loening, S Beckley, M F Brady, et al.
Journal of Surgical Oncology
|
June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
R P Gibbons, S Beckley, M F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Seminars in Oncology
|
October 1, 1996
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)
W P McGuire, W J Hoskins, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study
W P McGuire, W J Hoskins, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study
F M Muggia, P S Braly, M F Brady, et al.
Gynecologic Oncology
|
August 15, 2019
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218
K N Slaughter Wade, M F Brady, T Thai, et al.
Current Oncology (Toronto, Ont.)
|
October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
A M Oza, V Castonguay, D Tsoref, et al.
The Journal of Urology
|
January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area
M S Soloway, S Beckley, M F Brady, et al.
The Journal of Urology
|
May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer
S A Loening, S Beckley, M F Brady, et al.
Journal of Surgical Oncology
|
June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
R P Gibbons, S Beckley, M F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Page
of 5